AstraZeneca Partner's Orpathys Secures Renewal on China's Drug Reimbursement List
AstraZeneca's Breast Cancer Drug Wins State Insurance Coverage in China
AstraZeneca's Strategic Focus and Clinical Trial Success Bolster Buy Rating
Failure of AstraZeneca's AZD4041 a Blow for Non-opioid OUD Treatments
Amgen (AMGN.US) released mid-term data on the weight loss therapy MariTide, showing weight loss effects comparable to Novo Nordisk.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide achieved significant results in Phase 2 trials.
Astrazeneca (AZN.US) combination therapy Truqap phase 3 trial results are positive.
Astrazeneca (AZN.US) announced today the positive results of the CAPItello-281 Phase 3 clinical trial.
loading...
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
